Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. - Wikidata - wikimedia - TriplyDB

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

http://www.wikidata.org/entity/Q34302518

about

Cyclophosphamide therapy in pediatric multiple sclerosis Acquired pure red cell aplasia: updated review of treatment Role of immunosuppressive therapy for the treatment of multiple sclerosis Rare diseases.3: Wegener's granulomatosis Systemic sclerosis (scleroderma) and cancer risk: systematic review and meta-analysis of observational studies.Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Non-melanoma skin cancers and glucocorticoid therapy The safety profile of cyclophosphamide in multiple sclerosis therapy.Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.Switching multiple sclerosis patients with breakthrough disease to second-line therapy.Cyclophosphamide for the treatment of systemic lupus erythematosus.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.The downsides of a major medical advance Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms.Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Variability of the impact of adverse events on physicians' decision making Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis Comparison of cancer incidence among patients with rheumatic disease: a retrospective cohort study.Renal cell carcinoma with proliferative lupus nephritis.Risk of cancer among rheumatoid arthritis patients in California.Treatment of severe proliferative lupus nephritis: the current state.Maternal, pregnancy and fetal outcomes in de novo anti-glomerular basement membrane antibody disease in pregnancy: a systematic review.Mortality and causes of death in a Swedish series of systemic sclerosis patients.Cancer incidence among patients with ankylosing spondylitis in Sweden 1965-95: a population based cohort study.Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide Treating rheumatic patients with a malignancy.Considerations and management of a patient with three metachronous cancers in association with Lynch syndrome and ileal Crohn's disease: A case report.The British Society for Rheumatology Biologics Registers in Ankylosing Spondylitis (BSRBR-AS) study: Protocol for a prospective cohort study of the long-term safety and quality of life outcomes of biologic treatment.Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.Contemporary treatment of systemic lupus erythematosus: an update for clinicians.Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines New treatment strategies for proliferative lupus nephritis: keep children in mind!Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Regression of advanced melanoma upon withdrawal of immunosuppression: case series and literature review.Cyclosporin-A associated malignancy.

P2860

Q24630626-9D488810-5131-4154-BA0E-EB5BF4A716CF Q24652253-5EAA6485-4069-4199-8C0F-57615AD3833D Q26827467-9BB185D0-C8A8-4C6F-8815-59437A4F655F Q27477902-AD36BE79-7B19-48FD-BC55-CBF1939FFBDA Q27687340-9D7ECDA7-076A-4A1E-8352-F6D78E36E171 Q28216546-3376781D-F6FC-4C2F-A8FF-9E0F9CDDA4BA Q28348017-259EE4F3-3944-41FF-A0A9-101DF8C7030C Q31105891-FB6803FB-BEED-444F-A86C-260E1D1986C4 Q33321092-BE721F03-F47F-48B5-BFAA-6F34E6CAC988 Q33346685-8D2F1BB8-4C14-40AF-8A64-CDD3401B072A Q33715801-6D9FBCFE-4E55-4B09-8B0B-23B6A1497854 Q33815455-03A393BE-E742-4FD4-9E87-1DDCE71B8BDD Q34226984-DF4F3A53-617C-4450-A299-AB5EA47071C3 Q34257903-55CBE953-5499-414C-86B3-4C9DD47D59BE Q34345029-2D27441A-E6BA-4EB5-8669-80B83FD5F155 Q34409273-BA3988D3-8EEC-4192-8DD9-9670019CFCB8 Q34500502-2A85D303-C6E1-4F62-AE72-5CD6C8DB5C50 Q34538062-F815BD79-ED13-4C9A-9300-298ACFB2572B Q34922742-E6154CE3-DD8A-451A-94EC-B06B501D71EE Q34967765-05E13E81-0715-409A-80A4-438CF5D765CF Q35015758-6838FE59-9796-4F3B-AD10-22D57E1C9AF8 Q35162890-6C8D6B1D-48C8-49B3-901A-E7A3AF3851D7 Q35201234-CBA31ED4-49F5-43E3-9092-23F2E6F1D823 Q35232146-BE224AA9-D8F8-40F2-AAB4-76A9067CC414 Q35547607-AAB8FD5B-C115-4F72-BDB0-8EF1585A8C5D Q35552253-FF42A3DD-E75A-45A4-BCE2-431C63D97E22 Q35553364-D3DE3178-EF7E-4A95-97C5-9E7AE61684CC Q35557863-C416B081-15CF-4D75-B1D1-966547F89998 Q35601625-21F1FC61-F3C4-413F-ABDC-EA87420C93F3 Q35838797-16F1CE55-DD1A-4F89-B84D-17E98F0E44DF Q36145795-556FDFFB-1183-4D46-B35D-2FB17D4A0801 Q36443689-E2EB0833-DE0A-41F5-9B9B-1340277FB597 Q36464357-4B175B58-5A80-4092-9599-887A9CCCCA96 Q36514958-5F8A74B4-FE96-497E-9273-F612D063607E Q36724093-798BD303-C9E2-486D-9E43-4D88CD89C64F Q36915693-A5BFFE8A-5C74-46CC-8673-2E95794AC740 Q36964382-009EE0EA-D73E-479C-A477-288438DFBCAB Q36975701-ADFDA6EB-04DF-40D1-8E70-C14410F2DE92 Q37051177-1071C1A2-3CD4-416A-8148-854912251751 Q37247310-9BC1138C-FEC6-4980-A0AF-FEC25C28B080

P2860

Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study.

http://www.wikidata.org/entity/Q34302518

description

1995 nî lūn-bûn

@nan

1995 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1995 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1995年の論文

@ja

1995年論文

@yue

1995年論文

@zh-hant

1995年論文

@zh-hk

1995年論文

@zh-mo

1995年論文

@zh-tw

1995年论文

@wuu

name

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@ast

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@en

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@nl

type

label

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@ast

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@en

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@nl

prefLabel

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@ast

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@en

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@nl

P1433

Q34302518-1842898E-BC64-4A4D-B8A6-87C373D6F31E

P1476

Q34302518-68C9B4AD-3731-46F0-ADCE-ECAAEE8BF45B

P2093

Q34302518-16E60441-16CA-464A-81A0-E9A67EB753B8

Q34302518-4D9A4397-FC66-4055-A774-0CCEAFBE88CC

Q34302518-6BEDA5D9-701C-4F2E-A5C4-25CB2204DE34

Q34302518-785FAE71-0ACF-412D-9D9A-A0076F02BE2C

Q34302518-792AA696-CFE6-43BF-9230-501286693DD7

Q34302518-95100C79-BB82-45F1-BB93-36C869015779

Q34302518-9606D3C1-33CF-42E7-81FF-16B2E04678E0

Q34302518-C61B0F51-D02C-4D18-B2AA-6D5C66FC0684

Q34302518-E9A9C0CF-E8B0-429C-902E-0714E135F667

Q34302518-EEC4054F-6BE2-44D0-848C-9AF0DDC49D66

P2860

Q34302518-109A520E-92FE-4DCF-B397-E8EB322B9FCE

Q34302518-2D9C0313-D6A5-46FD-9EA1-7B4B677F85FA

Q34302518-53AE2F6C-70B7-4FDF-8AC5-52C4440A1EC6

P304

Q34302518-1EC0A9EE-C7BE-4C42-A313-D801C8F61EB8

P31

Q34302518-EF4445DC-DA4B-43A5-A303-44F2C5083F4E

P356

Q34302518-DDFA5BDF-C86A-44C6-B3F7-E8CE67F33175

P433

Q34302518-D15A8BEC-7401-4EEE-9F19-825478F26FF9

P478

Q34302518-CD39E373-E97A-4820-9084-1C377D87ED2F

P577

Q34302518-336A8BFA-B3B5-4DD2-A943-753CEEBC24C2

P698

Q34302518-A329A00E-E6CE-4B3A-8FD6-F83E01B018DE

P921

Q34302518-7AABE946-A0D6-40D7-A40E-295A963E6431

P356

P1433

Arthritis & Rheumatology

P1476

Effects of cyclophosphamide on ...... tis. A 20-year followup study.

@en

P2093

Agarwal AK

http://www.w3.org/2001/XMLSchema#string

Baker GL

http://www.w3.org/2001/XMLSchema#string

Cash JM

http://www.w3.org/2001/XMLSchema#string

Gallatin A

http://www.w3.org/2001/XMLSchema#string

Kahl LE

http://www.w3.org/2001/XMLSchema#string

Kwoh CK

http://www.w3.org/2001/XMLSchema#string

Medsger TA Jr

http://www.w3.org/2001/XMLSchema#string

Radis CD

http://www.w3.org/2001/XMLSchema#string

Stolzer BL

http://www.w3.org/2001/XMLSchema#string

Wasko MC

http://www.w3.org/2001/XMLSchema#string

P2860

Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis

Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years.

Wegener granulomatosis: an analysis of 158 patients.

P304

1120-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.1780380815

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

38

http://www.w3.org/2001/XMLSchema#string

P577

1995-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

7639809

http://www.w3.org/2001/XMLSchema#string

P921